WebCAI - Monoclonal Ab

Question 1

abciximab

Answer 1

platelet inhibitor - binds to GPIIb/IIIa

prevents the binding of fibrinogen and vWF to activated platelets

Question 2

infliximab

Answer 2

anti-TNF alpha

Question 3

toxlizumab

Answer 3

antagonist of IL-6 receptor

may increase CYP450 activity and increase metabolism of warfarin and cyclosporine

Question 4

palivizumab

Answer 4

RSV prophylaxis - give to premature infants/if they have other medical problems

IgG directed against an epitope in the A antigenic site of the F protein of RSV

Question 5

trastuzumab

Answer 5

used for metastatic breast cancer

binds to HER-2, causing internalization and downregulation of HER2

Question 6

bevacizumab

Answer 6

inhibits VEGF-A

used to prevent formation of new blood vessels in solid tumors

Question 7

basliximab

Answer 7

prevents graft rejection; binds to alopha chain of IL-2 receptor of T cells (CD25)

Question 8

daclizumab

Answer 8

prevents graft rejection; binds alpha subunit of IL2 receptor of T-cells (IE CD25)

Question 9

tositumomab

Answer 9

IgG2a lambda against CD20 antigen

used for non-Hodgkin lymphoma

Question 10

Reslizumab

Answer 10

IL-5 antagonist

(recall: IL-5 is a major cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophils)

Question 11

alemtuzumab

Answer 11

used for lymphoid malignancies: CLL, CTCL, and T cell lymphma

binds CD52

“alms guy”

Question 12

rituximab

Answer 12

anti-CD20

B cell malignancies

Question 13

anakinra

Answer 13

antagonist of IL-1 receptor

use: RA

Question 14

muromonab

Answer 14

prevents graft rejection; binds to CD3 receptor on T cells, thus blocking antigen presentation

first monoclonal Ab to be approved for clinical use in humans

Question 15

adalimumab

Answer 15

anti-TNF alpha

Question 16

omalizumab

Answer 16

asthma - binds to IgE bound to B-lymphocytes membranes

Question 17

gemtuzumab ozogamicin

Answer 17

off market

CD33 antigen = target

was used for myeloid leukemias

Question 18

Etanercept

Answer 18

anti-TNF alopha

note: is a dimeric fusion protein

Question 19

mepolizumab

Answer 19

IL-5 antagonist

(recall: IL-5 is a major cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophils)

Question 20

natalizumab

Answer 20

targets integrin molecules blocking the attachment on inflammatory cells to inflamed tissues

treats: Crohn disease and Multiple sclerosis

Question 21

vedolizumab

Answer 21

targets integrin molecules blocking the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue

Use: Crohn disease and ulcerative colitis

Question 22

abatacept

Answer 22

recombinant fusion protein composed of extracellular domain of CTLA-4 fused to human IgG (CD152)

increased CTLA-4 means increased inhibition of T cell activation